Results 161 to 170 of about 127,268 (310)

Minocycline and bone marrow–derived mononuclear cells as potential therapeutics for hereditary retinal degenerations

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To assess in Royal College of Surgeons (RCS) rats if the combination of two previously documented neuroprotective strategies: minocycline administration and bone marrow–derived mononuclear cells (BM‐MNCs) intravitreal transplantation, offers enhanced neuroprotection compared with each treatment alone.
Alba Videla‐Ristol   +6 more
wiley   +1 more source

The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In a cohort of IBS‐D patients recruited to the TRITON study, faecal metabolomic profiling reveals a SCFA‐enriched metabotype associated with increased pain and urgency, altered stool characteristics and accelerated intestinal transit. ABSTRACT Background Metabolomic analysis in irritable bowel syndrome (IBS) has identified metabotypes enriched in ...
T. E. Conley   +8 more
wiley   +1 more source

Distinct regional patterns of synaptic vulnerability across hippocampal and parahippocampal subregions in Alzheimer's disease

open access: yesBrain Pathology, EarlyView.
Synaptic loss in Alzheimer's disease predominantly affects the entorhinal cortex and parahippocampal gyrus. Amyloid‐β and p‐tau pathology show global associations with synaptic density but are limited in specific subregions. Instead, axonal damage associates with synaptic loss locally and in interconnected subregions.
Maud M. A. Bouwman   +4 more
wiley   +1 more source

Can Reprogramming Taste Modulate Excess Food Intake?

open access: yes
Obesity, EarlyView.
Kerstin Rohde‐Zimmermann   +1 more
wiley   +1 more source

Psilocybin as a novel treatment for chronic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey   +3 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy